Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Phase 1

Completed

Conditions: Leukemia
Multiple Myeloma

Interventions: Drug: CIK cells
Drug: etoposide
Drug: bcnu
Drug: cyclophosphamide
Drug: gemcitabine
Drug: vinorelbine
Drug: melphalan

First Posted Date: 2007-05-22

Last Posted Date: 2017-01-11

Lead Sponsor: Sally Arai

Target Recruit Count: 22

Registration Number: NCT00477035

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

ALL Adult Consortium Trial: Adult ALL Trial

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Doxorubicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Methylprednisone
Drug: Hydrocortisone Sodium Succinate
Drug: Dexamethasone
Drug: 6-MP
Drug: PEG-Asparaginase
Drug: Imatinib
Drug: Etoposide
Procedure: Radiation Therapy
Drug: E. coli Asparaginase

First Posted Date: 2007-05-21

Last Posted Date: 2024-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 112

Registration Number: NCT00476190

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Boston, Boston, Massachusetts, United States

and more 12 locations

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Drug: Rituximab

First Posted Date: 2007-05-11

Last Posted Date: 2016-03-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 93

Registration Number: NCT00472056

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Phase 3

Active, not recruiting

Conditions: Sarcoma

Interventions: Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: methotrexate
Drug: zoledronic acid
Procedure: conventional surgery

First Posted Date: 2007-05-07

Last Posted Date: 2024-04-18

Lead Sponsor: UNICANCER

Target Recruit Count: 318

Registration Number: NCT00470223

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
CHR de Besancon - Hopital Saint-Jacques, Besancon, France
🇫🇷
CHU Hopital A. Morvan, Brest, France

and more 34 locations

Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2007-04-11

Last Posted Date: 2019-02-15

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 470

Registration Number: NCT00458848

Locations: 🇮🇹
Ospedale S. Donato, Arezzo, Italy
🇮🇹
S.G. Moscati Hospital, Avellino, Italy
🇮🇹
Ospedale Binaghi, Cagliari, Italy

and more 63 locations

Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Teratoma
Testicular Germ Cell Tumor

First Posted Date: 2007-03-28

Last Posted Date: 2013-08-07

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 20

Registration Number: NCT00453232

Locations: 🇬🇧
Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom
🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom

and more 4 locations

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Extensive Stage Lung Small Cell Carcinoma
Recurrent Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Sunitinib Malate

First Posted Date: 2007-03-28

Last Posted Date: 2023-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT00453154

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Heartland Cancer Research NCORP, Decatur, Illinois, United States
🇺🇸
Illinois CancerCare-Princeton, Princeton, Illinois, United States

and more 122 locations